Lipopolysaccharide induces interleukin-8 production by human cervical smooth muscle cells

J Soc Gynecol Investig. 2003 Feb;10(2):110-7. doi: 10.1016/s1071-5576(02)00219-8.

Abstract

Objective: We examined the effect of lipopolysaccharide (LPS), a component of the outer wall of gram-negative bacteria, on expression of the neutrophil chemoattractant interleukin-8 (IL-8) and the effects of IL-8 treatment on release of matrix metabolizing enzymes in human cervical smooth muscle cells (CSMCs).

Methods: Human CSMCs were exposed to Escherichia coli LPS, and the expression of IL-8 mRNA was analyzed by Northern blotting. The IL-8 promoter activity was examined by dual luciferase assay, and the IL-8 concentration was assessed by enzyme-linked immunosorbent assay. We also treated the CSMCs with human IL-8 and examined the expression of matrix-degrading enzymes.

Results: E coli LPS (100 ng/mL) increased the expression of IL-8 mRNA 12.8-fold after 3 hours. This up-regulation was maintained for up to 24 hours. Lipopolysaccharide treatment produced a fivefold increase in IL-8 promoter activity in CSMCs transfected with an IL-8 promoter-reporter construct. IL-8 concentrations in conditioned medium of CSMC cultures treated with E coli LPS increased approximately 18-fold compared with the control cultures. Northern blot analysis and zymography revealed that exogenous human IL-8 had no significant effect on the expression of matrix metalloproteinase (MMP)-1, -3, and tissue inhibitor of metalloproteinase (TIMP)-1 mRNAs, and on the secretion MMP-2 and -9 in CSMCs.

Conclusion: We conclude that CSMCs respond to LPS with increased expression of IL-8 mRNA and secreted IL-8, and that expression of matrix metabolizing enzymes in CSMCs is not directly affected by IL-8. IL-8 produced by CSMCs in response to gram-negative infection may promote neutrophil invasion, and release of neutrophil matrix-degrading enzymes may participate in the matrix remodeling associated with parturition.

MeSH terms

  • Cells, Cultured
  • Cervix Uteri / cytology*
  • Cervix Uteri / metabolism
  • Dactinomycin / pharmacology
  • Escherichia coli
  • Female
  • Gene Expression / drug effects
  • Humans
  • Interleukin-8 / genetics
  • Interleukin-8 / metabolism*
  • Interleukin-8 / pharmacology
  • Lipopolysaccharides / pharmacology*
  • Matrix Metalloproteinase 1 / drug effects
  • Matrix Metalloproteinase 1 / genetics
  • Matrix Metalloproteinase 2 / drug effects
  • Matrix Metalloproteinase 2 / metabolism
  • Matrix Metalloproteinase 3 / drug effects
  • Matrix Metalloproteinase 3 / genetics
  • Matrix Metalloproteinase 9 / drug effects
  • Matrix Metalloproteinase 9 / metabolism
  • Muscle, Smooth / cytology
  • Muscle, Smooth / drug effects
  • Muscle, Smooth / metabolism*
  • Promoter Regions, Genetic
  • RNA, Messenger / drug effects
  • Tissue Inhibitor of Metalloproteinase-1 / drug effects
  • Tissue Inhibitor of Metalloproteinase-1 / genetics

Substances

  • Interleukin-8
  • Lipopolysaccharides
  • RNA, Messenger
  • Tissue Inhibitor of Metalloproteinase-1
  • Dactinomycin
  • Matrix Metalloproteinase 3
  • Matrix Metalloproteinase 2
  • Matrix Metalloproteinase 9
  • Matrix Metalloproteinase 1